

1Pw


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 21, 2006

Signature: Katlyn Nelson

(Katelyn Nelson)

Docket No.: WYS-020.02
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Pre Patent Application of:

John G. Gribben *et al.*

Application No.: 10/732,847

Confirmation No.: 9329

Filed: December 9, 2003

Art Unit: 1644

For: METHODS OF INHIBITING T CELL
PROLIFERATION OR IL-2
ACCUMULATION WITH CTLA-4
SPECIFIC ANTIBODIES

Examiner: P. Gambel

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO form 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)) and thus no fees are believed to be due in connection with this submission.

Copies of references AA-CZ are not provided to the examiner since they were cited in parent application 08/253,783 filed June 3, 1994, now U.S. Patent 6,719,972. All references cited

in parent application 08/253,783, now U.S. Patent 6,719,972 are hereby brought to the attention of the examiner.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-1448, under Reference No. WYS-020.02.

Dated: February 21, 2006

Respectfully submitted,

By 

DeAnn F. Smith

Registration No.: 36,683

FOLEY HOAG LLP

155 Seaport Blvd

Boston, Massachusetts 02210

(617) 832-1264

Attorney for Applicants



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/732,847	
			Filing Date	December 9, 2003	
			First Named Inventor	John G. Gribben	
			Art Unit	1644	
			Examiner Name	P. Gambel	
Sheet	1	of	2	Attorney Docket Number	WYS-020.02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,434,131	07-18-1995	Peter S. Linsley	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-93/00431	01/1993			
	BB	WO-93/19767	10/1993			
	BC	WO-94/03202	02/1994			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	KRUMMEL et al. J Exp Med 183: 2533-2540 (1996).	
	CB	BLUESTONE Immunity 2: 555-559 (1995).	
	CC	RUDIN et al. Curr. Opin. Hematol. 3: 35-40 (1996).	
	CD	YI-QUN et al. Intl. Immunol. 8: 37-44 (1996).	
	CE	BLAZAR et al. J. Immunol. 157: 3250-3259 (1996).	
	CF	KAHAN Curr. Opin. Immunol. 4: 553-560 (1992).	
	CG	GRIBBEN et al. PNAS 92: 811-815 (1995).	
	CH	WALUNAS et al. J Exp Med 183: 2541-2550 (1996).	
	CI	PERRIN et al. J. Neuroimmunology 65: 31-39 (1996).	
	CJ	PAUL (ED) Fundamental Immunology Raven Press NY 1993 p. 242.	
	CK	COYLE et al. Nature Immunology 2: 203-209 (2001).	
	CL	SKULNICK et al. Trends Biotech. 18: 34-39 (2000).	
	CM	Ngo et al. in the Protein Folding Problem and Tertiary Structure Prediction 1994 Merz et al. (ED) Birkhauser, Boston MA. pp. 433, 492-495.	
	CN	MUELLER Current Biology 10: 12227-12230 (2000).	
	CO	YANG et al. J. Exp. Med. 168: 1457-1468 (1988).	
	CP	LINDSTEN, T., et al., (1993) "Characterization CTLA-4 Structure and Expression on Human T Cells", The Journal of Immunology, vol. 151, No. 7, pp. 3489-3499.	
	CQ	HARPER, K., et al., (1991) "CTLA-4 and CD28 Activated Lymphocyte Molecules are Closely Related in Both Mouse and Human as to Sequence, Message Expression, Gene Structure, and Chromosomal Location", The Journal of Immunology, vol. 147, No. 3, pp. 1037-1044.	
	CR	JELLIS, C.L., et al., (1993) "Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies", Gene, vol. 137, pp. 63-68.	
	CS	LINSLEY, P.S., et al., (1992) "Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes", J. Exp. Med., vol. 176, pp. 1595-1604.	
	CT	DARZYNKIEWICZ, Z., et al., (1992) "Features of Apoptic Cells Measured by Flow Cytometry", Cytometry, vol. 13, pp. 795-808.	
	CU	FREEMAN, G.J., et al., (1992) "CTLA-4 and CD28 mRNA are Coexpressed in most T Cells after Activation", The Journal of Immunology, vol. 149, No. 12, pp. 3795-3801.	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/732,847
				Filing Date	December 9, 2003
				First Named Inventor	John G. Gribben
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	2	of	2	Attorney Docket Number	WYS-020.02

CV	HARDIN, J.A., et al., (1992) "A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation", Journal of Immunological Methods, vol. 154, pp. 99-107.	
CW	LINSLEY, P.S., et al., (1991) "CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7", J. Exp. Med., vol. 164, pp. 561-569.	
CX	DARIAVACH, P., et al., (1988) "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains", Eur. J. Immunol., vol. 18, pp. 1901-1905.	
CY	BRUNET, Jean-Francois, et al., (1987) "A new member of the immunoglobulin superfamily--CTLA-4", Nature, vol. 328, pp. 267-270.	
CZ	KUNTZ et al. Science 257: 1078-1082 (1992).	
DA	NAGATA, S. et al., (1995) "The Fas Death Factor", Science, Vol. 267 pp.1449-1456.	
DB	BOUSSIOTIS, V. et al., (1993) "Activated Human B Lymphocytes Express Three CTLA-4 Counterreceptors that Costimulate T-cell Activation", PNAS, Vol. 90, pp.11059-11063.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--